# Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

> **NCT04423718** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 1011 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)
- **DRUG:** Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)

## Key facts

- **NCT ID:** NCT04423718
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-11
- **Primary completion:** 2022-07-27
- **Final completion:** 2024-08-07
- **Target enrollment:** 1011 (ACTUAL)
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04423718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04423718, "Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04423718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*